Send to

Choose Destination
Mol Cell Oncol. 2015 Feb 3;2(4):e1001199. doi: 10.1080/23723556.2014.1001199. eCollection 2015 Oct-Dec.

Boosting NAD(+) for the prevention and treatment of liver cancer.

Author information

Cancer Cell Biology Programme; Growth Factors, Nutrients and Cancer Group; Spanish National Cancer Research Centre ; Madrid, Spain.


Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide yet has limited therapeutic options. We recently demonstrated that inhibition of de novo nicotinamide adenine dinucleotide (NAD(+)) synthesis is responsible for DNA damage, thereby initiating hepatocarcinogenesis. We propose that boosting NAD(+) levels might be used as a prophylactic or therapeutic approach in HCC.


Aryl hydrocarbon receptor (AhR); DNA damage; Estrogen receptor (ER); GEMMs; HCC; NAD+; URI; nicotinamide riboside; pancreatic tumor; prevention; therapy

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center